From: Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision
 | Frequency N (%) |  | |||
---|---|---|---|---|---|
Surgery alone (n = 60; 50%) | 5-FU therapy (n = 60; 50%) | p | |||
Clinical-pathological features | Age, mean (SD), years | Â | 67.4 (10.44) | 67.7 (10.8) | 0.9 |
Sex | Male | 28 (47) | 29 (48) | 0.3 | |
Female | 32 (53) | 31 (52) | |||
Tumour location 1 | Proximal | 21 (35) | 25 (42) | 0.4 | |
Distal | 39 (65) | 35 (58) | |||
Tumour grade | G1 | 8 (13) | 8 (13) | 0.5 | |
G2 | 51 (85) | 49 (82) | |||
G3 | 1 (2) | 3 (5) | |||
Depth of tumour invasion | pT3 | 53 (88) | 53 (88) | 1.0 | |
pT4 | 7 (12) | 7 (12) | |||
Lymphovascular invasion | No | 39 (65) | 37 (62) | 0.8 | |
Yes | 21 (35) | 22 (38) | |||
Large veins invasion | No | 51 (85) | 47 (78) | 0.3 | |
Yes | 9 (15) | 13 (22) | |||
Tumour infiltrating lymphocytes | No | 53 (88) | 48 (80) | 0.2 | |
Yes | 7 (12) | 12 (20) | |||
Chron’s like reaction | No | 31 (52) | 27 (45) | 0.4 | |
Yes | 29 (48) | 33 (55) | |||
Tumour border configuration | Pushing | 56 (93) | 51 (85) | 0.2 | |
Infiltrating | 4 (7) | 9 (15) | |||
Molecular parameters | MMR system | dMMR | 8 (13) | 10 (17) | 0.6 |
pMMR | 52 (87) | 50 (83) | |||
CIMP | CIMP-High | 8 (13) | 14 (23) | 0.3 | |
CIMP-Low | 18 (30) | 18 (30) | |||
CIMP-0 | 34 (57) | 28 (47) | |||
TYMS mRNA expression | High level | 24 (40) | 33 (55) | 0.1 | |
Low level | 36 (60) | 27 (45) | |||
TYMS protein expression (IHC) | High | 30 (50) | 28 (47) | 0.7 | |
Low | 30 (50) | 32 (53) | |||
TP53 | Positive | 24 (40) | 22 (37) | 0.7 | |
Negative | 36 (60) | 38 (63) | |||
CTNNB12 Cytoplasmic localization | Positive | 41 (68) | 41 (69) | 0.8 | |
Negative | 19 (32) | 18 (31) | |||
CTNNB12 Nuclear localization | Positive | 18 (30) | 26 (44) | 0.1 | |
Negative | 42 (70) | 33 (56) | |||
CTNNB12 Membrane localization | Positive | 27 (45) | 19 (32) | 0.1 | |
Negative | 33 (55) | 40 (68) | |||
BRAF c.1799 T > A | Wild type | 51 (85) | 52 (87) | 1.0 | |
 |  | Mutated | 9 (15) | 8 (13) |  |